Veraxa Biotech is trading at $1.03, down 6.76%, with the reason for the decline unclear. - No company-specific announcement dated October 19 was found; the latest company release, on October 13, covered BiTAC-ADC proof-of-concept data. - Available coverage does not identify a clear catalyst or report unusual-volume activity. - The supplied broader-market context is positive and does not explain the decline.